U.S. CRO Theorem Clinical Research is investing in its overseas infrastructure, setting up a new clinical supplies facility in Germany to speed up trials on the continent.
Bavarian Nordic is the latest company to benefit from the European Investment Bank's newfound willingness to finance drug development, snagging access to up to €50 million ($56 million) in loans for its Ebola and immunotherapy programs.
Global CRO QPS Holdings opened a new lab devoted to in vitro research, setting up shop in Fargo, ND, with eyes on early-stage partnerships.
Despite years of efforts from academia and the industry, including Merck, no FDA-approved West Nile virus vaccine exists. Scientists from Oregon Health & Science University are looking to change that.
Billionaire entrepreneur Patrick Soon-Shiong has raised $100 million for one of the many offshoots of his NantWorks conglomerate, working to duplicate the success of the targeted cancer drug that helped build his empire.
A South Korean team is making progress on the fourth-generation stent.
Many delivery platforms are based in part on organisms existing in nature, such as bacteria or viruses, and now researchers at Massachusetts General Hospital have turned to the common Escherichia coli bacterium and instilled it with a natural ability to transport proteins.
NewLink Genetics rattled investors after the markets closed on Monday, saying it will need to cruise past its second planned interim analysis for a late-stage cancer vaccine without any change to the trial. No news is bad news as far as the market is concerned.
Google's Baseline study is getting a boost, with a Harvard cardiologist moving over to lead the initiative almost a year after the company revealed its plans to aggregate molecular and genetic data to jump-start medical research.
Shuffling a thick deck of preclinical programs, Moderna Therapeutics has dealt out a fresh biotech hand for the third in its series of venture units tasked with recruiting a new team to shepherd messenger RNA programs into the clinic.